NCT07532213 (LUNAR) is a clinical trial in Inflammatory Bowel Disease, sponsored by Janssen-Cilag A.G., Switzerland.

Who is sponsoring NCT07532213?

NCT07532213 is sponsored by Janssen-Cilag A.G., Switzerland.

What condition does NCT07532213 study?

NCT07532213 studies Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease.

Is NCT07532213 still recruiting?

NCT07532213 is currently not yet recruiting. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07532213: LUNAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Not yet recruiting Last updated 15 April 2026

What this trial tests

trial in Inflammatory Bowel Disease in 50 participants. Not yet recruiting.

Timeline

23 April 2026

Primary endpoint
10 April 2029

10 April 2029

Quick facts

Lead sponsor	Janssen-Cilag A.G., Switzerland
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	50
Start date	23 April 2026
Primary completion	10 April 2029
Estimated completion	10 April 2029

Conditions studied

Inflammatory Bowel Disease — all drugs for Inflammatory Bowel Disease →
Colitis, Ulcerative — all drugs for Colitis, Ulcerative →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

Janssen-Cilag A.G., Switzerland — full company profile →

Who can join

18 and older, any sex, with Inflammatory Bowel Disease or Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Disease

Currently open trials in the same condition.

NCT07210580 — Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory · NA · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT07252427 — Gut Microbiota in IBD With Comorbid Depressive Disorder · recruiting
NCT06781827 — Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07532213 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag A.G., Switzerland
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07532213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing